Literature DB >> 10608023

Plasminogen Activator Inhibitor 1: Molecular Aspects and Clinical Importance.

.   

Abstract

Plasminogen activator inhibitor-1 (PAI-1) is the major physiologic inhibitor of plasminogen activation in plasma and in the blood vessel wall. PAI-1 exhibits distinctive structural and functional properties that have been extensively studied over the past decade. Aside from the physiological role of PAI-1, there is accumulating evidence that increased production of PAI-1 may contribute to the development of ischemic cardiovascular disease. Efforts are now underway to develop and test specific inhibitors of PAI-1.

Entities:  

Year:  1995        PMID: 10608023     DOI: 10.1007/bf01062709

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  67 in total

1.  Plasminogen activator inhibitor from human fibrosarcoma cells binds urokinase-type plasminogen activator, but not its proenzyme.

Authors:  P A Andreasen; L S Nielsen; P Kristensen; J Grøndahl-Hansen; L Skriver; K Danø
Journal:  J Biol Chem       Date:  1986-06-15       Impact factor: 5.157

Review 2.  Receptor-mediated endocytosis of plasminogen activators and activator/inhibitor complexes.

Authors:  P A Andreasen; L Sottrup-Jensen; L Kjøller; A Nykjaer; S K Moestrup; C M Petersen; J Gliemann
Journal:  FEBS Lett       Date:  1994-02-07       Impact factor: 4.124

3.  Human plasminogen activator inhibitor-1 gene. Promoter and structural gene nucleotide sequences.

Authors:  P J Bosma; E A van den Berg; T Kooistra; D R Siemieniak; J L Slightom
Journal:  J Biol Chem       Date:  1988-07-05       Impact factor: 5.157

4.  Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction.

Authors:  A Hamsten; U de Faire; G Walldius; G Dahlén; A Szamosi; C Landou; M Blombäck; B Wiman
Journal:  Lancet       Date:  1987-07-04       Impact factor: 79.321

5.  Specific glycosaminoglycans support the inhibition of thrombin by plasminogen activator inhibitor 1.

Authors:  R K Gebbink; C H Reynolds; D M Tollefsen; K Mertens; H Pannekoek
Journal:  Biochemistry       Date:  1993-02-16       Impact factor: 3.162

6.  Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis.

Authors:  P Carmeliet; J M Stassen; L Schoonjans; B Ream; J J van den Oord; M De Mol; R C Mulligan; D Collen
Journal:  J Clin Invest       Date:  1993-12       Impact factor: 14.808

7.  Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin).

Authors:  P J Declerck; M De Mol; M C Alessi; S Baudner; E P Pâques; K T Preissner; G Müller-Berghaus; D Collen
Journal:  J Biol Chem       Date:  1988-10-25       Impact factor: 5.157

8.  Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis.

Authors:  D E Vaughan; S A Lazos; K Tong
Journal:  J Clin Invest       Date:  1995-03       Impact factor: 14.808

9.  Circadian variation in the efficacy of tissue-type plasminogen activator.

Authors:  P B Kurnik
Journal:  Circulation       Date:  1995-03-01       Impact factor: 29.690

10.  Endothelial plasminogen activator inhibitor (PAI): a new member of the Serpin gene family.

Authors:  H Pannekoek; H Veerman; H Lambers; P Diergaarde; C L Verweij; A J van Zonneveld; J A van Mourik
Journal:  EMBO J       Date:  1986-10       Impact factor: 11.598

View more
  1 in total

1.  Plasminogen activator inhibitor-1 antagonist TM5441 attenuates Nω-nitro-L-arginine methyl ester-induced hypertension and vascular senescence.

Authors:  Amanda E Boe; Mesut Eren; Sheila B Murphy; Christine E Kamide; Atsuhiko Ichimura; David Terry; Danielle McAnally; Layton H Smith; Toshio Miyata; Douglas E Vaughan
Journal:  Circulation       Date:  2013-10-03       Impact factor: 29.690

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.